Blood Cancer United Receives $7.5 Million From Royalty Pharma for Therapy Program
Royalty Pharma has donated $7.5 million to Blood Cancer United to expand its therapy acceleration program. The funds will support the development of new blood cancer treatments.
Blood Cancer United announced it has received a $7.5 million donation from Royalty Pharma. The funds are designated to expand the organization's venture philanthropy program, which aims to accelerate the development of new therapies for blood cancers.
The donation signifies a new phase for Blood Cancer United's program, which operates on a model where returns from investments are reinvested to support future therapeutic initiatives. This approach seeks to create a sustainable funding mechanism for advancing blood cancer research and treatment.
According to Blood Cancer United, the capital will be used to enhance its existing therapy program. This program focuses on identifying and supporting promising treatments in their early stages. The organization has not yet detailed specific projects that will receive funding.
Royalty Pharma, a company specializing in pharmaceutical investments, has made this contribution to further its goal of advancing medical treatments. The partnership highlights the role of private funding in supporting scientific advancement in the healthcare sector.